Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Valerius

Showing results (21-30 of 106) with videos related to

Pageof 11
Sort By:
Intensive Care Medicine|August 22, 2024
Management of chimeric antigen receptor T (CAR-T) cell-associated toxicitiesTorsten Schroeder, Tjark Martens, Lars Fransecky, et al.
British Journal of Haematology|August 30, 2002
Enhanced killing of B lymphoma cells by granulocyte colony-stimulating factor-primed effector cells and Hu1D10--a humanized human leucocyte antigen DR antibodyBernhard Stockmeyer, Martin Schiller, Roland Repp, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 27, 2012
Impact of epidermal growth factor receptor (EGFR) cell surface expression levels on effector mechanisms of EGFR antibodiesStefanie Derer, Philip Bauer, Stefan Lohse, et al.
Frontiers in Oncology|December 11, 2024
Sialylation inhibition improves macrophage mediated tumor cell phagocytosis of breast cancer cells triggered by therapeutic antibodies of different isotypesMarta Lustig, Christoph Hahn, Marie Leangen Herigstad, et al.
Oncotarget|November 5, 2017
A novel Fc-engineered human ICAM-1/CD54 antibody with potent anti-myeloma activity developed by cellular panning of phage display librariesKatja Klausz, Michael Cieker, Christian Kellner, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 22, 2007
Effector mechanisms of recombinant IgA antibodies against epidermal growth factor receptorMichael Dechant, Thomas Beyer, Tanja Schneider-Merck, et al.
Frontiers in Immunology|December 16, 2020
Specific Targeting of Lymphoma Cells Using Semisynthetic Anti-Idiotype Shark AntibodiesArturo Macarrón Palacios, Julius Grzeschik, Lukas Deweid, et al.
American Journal of Nephrology|October 26, 2013
Antibody-dependent cellular cytotoxicity in patients on chronic hemodialysisTill Koch, Stefanie Derer, Matthias Staudinger, et al.
Molecular Immunology|June 30, 2020
Recruitment of properdin by bi-specific nanobodies activates the alternative pathway of complementDennis V Pedersen, Thies Rösner, Annette G Hansen, et al.
Blood|October 24, 2002
Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killingMichael Dechant, Gestur Vidarsson, Bernhard Stockmeyer, et al.
Pageof 11

Showing results (21-30 of 106) with videos related to

Sort By:
Pageof 11
Intensive Care Medicine|August 22, 2024
Management of chimeric antigen receptor T (CAR-T) cell-associated toxicitiesTorsten Schroeder, Tjark Martens, Lars Fransecky, et al.
British Journal of Haematology|August 30, 2002
Enhanced killing of B lymphoma cells by granulocyte colony-stimulating factor-primed effector cells and Hu1D10--a humanized human leucocyte antigen DR antibodyBernhard Stockmeyer, Martin Schiller, Roland Repp, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 27, 2012
Impact of epidermal growth factor receptor (EGFR) cell surface expression levels on effector mechanisms of EGFR antibodiesStefanie Derer, Philip Bauer, Stefan Lohse, et al.
Frontiers in Oncology|December 11, 2024
Sialylation inhibition improves macrophage mediated tumor cell phagocytosis of breast cancer cells triggered by therapeutic antibodies of different isotypesMarta Lustig, Christoph Hahn, Marie Leangen Herigstad, et al.
Oncotarget|November 5, 2017
A novel Fc-engineered human ICAM-1/CD54 antibody with potent anti-myeloma activity developed by cellular panning of phage display librariesKatja Klausz, Michael Cieker, Christian Kellner, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 22, 2007
Effector mechanisms of recombinant IgA antibodies against epidermal growth factor receptorMichael Dechant, Thomas Beyer, Tanja Schneider-Merck, et al.
Frontiers in Immunology|December 16, 2020
Specific Targeting of Lymphoma Cells Using Semisynthetic Anti-Idiotype Shark AntibodiesArturo Macarrón Palacios, Julius Grzeschik, Lukas Deweid, et al.
American Journal of Nephrology|October 26, 2013
Antibody-dependent cellular cytotoxicity in patients on chronic hemodialysisTill Koch, Stefanie Derer, Matthias Staudinger, et al.
Molecular Immunology|June 30, 2020
Recruitment of properdin by bi-specific nanobodies activates the alternative pathway of complementDennis V Pedersen, Thies Rösner, Annette G Hansen, et al.
Blood|October 24, 2002
Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killingMichael Dechant, Gestur Vidarsson, Bernhard Stockmeyer, et al.
Pageof 11